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Abstract
A broad spectrum of beneficial effects has been ascribed to creatine (Cr), phosphocreatine (PCr) and their cyclic analogues
cyclo-(cCr) and phospho-cyclocreatine (PcCr). Cr is widely used as nutritional supplement in sports and increasingly also as
adjuvant treatment for pathologies such as myopathies and a plethora of neurodegenerative diseases. Additionally, Cr and
its cyclic analogues have been proposed for anti-cancer treatment. The mechanisms involved in these pleiotropic effects are
still controversial and far from being understood. The reversible conversion of Cr and ATP into PCr and ADP by creatine
kinase, generating highly diffusible PCr energy reserves, is certainly an important element. However, some protective effects
of Cr and analogues cannot be satisfactorily explained solely by effects on the cellular energy state. Here we used mainly
liposome model systems to provide evidence for interaction of PCr and PcCr with different zwitterionic phospholipids by
applying four independent, complementary biochemical and biophysical assays: (i) chemical binding assay, (ii) surface
plasmon resonance spectroscopy (SPR), (iii) solid-state 31P-NMR, and (iv) differential scanning calorimetry (DSC). SPR
revealed low affinity PCr/phospholipid interaction that additionally induced changes in liposome shape as indicated by NMR
and SPR. Additionally, DSC revealed evidence for membrane packing effects by PCr, as seen by altered lipid phase transition.
Finally, PCr efficiently protected against membrane permeabilization in two different model systems: liposome-
permeabilization by the membrane-active peptide melittin, and erythrocyte hemolysis by the oxidative drug doxorubicin,
hypoosmotic stress or the mild detergent saponin. These findings suggest a new molecular basis for non-energy related
functions of PCr and its cyclic analogue. PCr/phospholipid interaction and alteration of membrane structure may not only
protect cellular membranes against various insults, but could have more general implications for many physiological
membrane-related functions that are relevant for health and disease.
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Introduction
The guanidino compounds creatine (Cr) and phosphocreatine
(PCr) belong to the most abundant cellular metabolites in
mammals including humans, with about 120 g present in a 70 kg
adult male [1]. Tissues such as muscle or brain maintain a total
cellular Cr pool of up to 30–40 mM [1]. Cr exerts a large number
of pleiotropic beneficial physiological and pharmacological effects
in vitro and in vivo. These include protective effects against hypoxic,
ischemic, oxidative, neurodegenerative or muscular damage, and
possibly also beneficial effects for healthy subjects in respect to life
expectancy and life quality, learning and memory or during
pregnancy (reviewed in [1–6]). The beneficial effects of Cr
supplementation were first reported for muscle growth, perfor-
mance and rehabilitation in sports [7–10]. More recently,
protective effects were observed in animal models of various
pathologies and also in some clinical studies [11–14], proposing Cr
supplementation as a valuable clinical strategy for muscle and
bone growth and maintenance, as well as for general cell- and
neuroprotection (reviewed in [5,15,16]).
About 50% of the daily requirement of Cr is obtained by
endogenous synthesis in the body, mainly in kidney and liver, the
remainder comes from nutrition, principally fish and meat. Cr is
taken up into cells by a specific Cr transporter [4,17]. In cells, the
isoforms of creatine kinase (CK) reversibly convert about two
thirds of the total Cr pool into PCr. With intracellular
concentrations up to 30–40 mM and its rapid diffusibility, PCr
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together with CK isoforms provides an efficient energy buffer and
transport system that maintains cellular energy homeostasis by
restoring global and local ATP pools [5,16,18]. Thus, most Cr is
found in cells with high and variable energy requirements such as
myocytes or neurons. Some evidence suggests that beneficial
effects of Cr depend on the presence of CK and increased PCr
generation [4,19,20].
Energy-related functions of the CK/PCr system may well
explain the ergogenic effects of Cr on muscle performance in
sports and clinics [10], but may be insufficient for other pleiotropic
Cr effects observed in complex pathologies like neurodegenerative
disease or aging, including altered cell signaling, protein expression
and cell protection in general [9,10,21,22]. In a Drosophila model, it
was shown that Cr alone can protect from oxidative stress,
although insects, expressing arginine kinase instead or CK, are not
capable to synthesize PCr [23,24]. Mechanistic aspects were also
raised for effects observed with synthetic Cr analogues, in
particular cyclocreatine (cCr). An anti-tumor activity of cCr
observed in vitro [25–27] and in transplanted tumors [28,29] was
initially explained by energy depletion due to trapping of high
energy phosphates via the CK reaction into PcCr, a poor substrate
in the CK reverse reaction [30]. However, follow-up studies
showed that Cr itself also displays anti-tumor activity [29,31] and
that Cr and cCr can have beneficial effects in neuroprotection [32]
and as a potential treatment for cognitive dysfunctions in Cr
transporter deficiency [33], respectively. These data rather exclude
purely energy-related mechanisms of Cr and congeners, at least in
these studies.
Different alternative mechanisms for Cr action have already
been proposed. Mitochondrial CK could mediate anti-oxidative or
anti-apoptotic effects by maintaining local substrate cycling with
inhibitory effects on mitochondrial ROS production and pro-
apoptotic permeability transition [34–36]. However, mitochon-
drial CK seems to be dispensable for at least some protective
effects [37]. Cr was further proposed to exert direct antioxidant
effects [38–41], activate signaling pathways like Akt/PKB
[9,10,21,42] or AMPK [43], leading to increased expression of
muscle transcription factors [9,10,21] and enzymes for oxidative
stress defense [22]. However, Cr in vitro is not an effective
antioxidant, and Cr may not directly affect cell signaling, as e.g.
direct activation of AMPK by PCr/Cr ratios [44] has been
questioned [45,46].
Here, we propose a novel direct molecular mechanism of Cr
action, involving molecular interaction mainly of PCr with
membrane phospholipids. This leads to membrane protection
and stabilization, possibly affecting additional membrane-based
processes like ion homeostasis and cell signaling. Earlier observa-
tions showed that exogenous PCr in cardioplegic solution is
cardioprotective, although external PCr is unlikely to transverse
cardiac plasma membranes [47]. A possible mechanism could be
inferred, however, from ESR data that already suggested that PCr
may be able to interact with membranes and to increase
membrane packing [48,49]. In support of this notion, more recent
proton NMR studies on human muscle tissue suggested a motion-
ally restricted Cr/PCr pool bound to cellular structures, possibly
phospholipids of cellular membranes [50,51].
In the present study, we directly tested lipid interaction of
both, Cr and PCr, as well as their cyclic analogues cCr and
PcCr, using independent biochemical and biophysical assays.
The results demonstrate a low affinity interaction in particular
of the phospho-compounds, PCr and PcCr, with zwitterionic
phospholipids. They further reveal changes in phospholipid
bilayer properties by membrane-bound PCr, and a resulting
protection of lipid membranes against permeabilization and cell
lysis. These findings propose a novel mechanism for the
biological functions of Cr and PCr acting at membranes, in
addition to the known energy-related functions, both with
relevance for human health and disease.
Materials and Methods
Materials
Cr was from Sigma (Munich, Germany), PCr from Calbiochem
(La Jolla, CA, USA), cCr and PcCr from Avicena (Cambridge,
MA, USA), glucose-6-phosphate from Applichem (Darmstadt,
Germany). If not stated otherwise, chemicals were from Sigma-
Aldrich (Buchs, Switzerland).
Large Unilamellar Vesicles (LUVs)
Lipid stock suspensions at 5 mg/ml in 10 mM TES, pH 7.0,
50 mM NaCl were prepared as described [52]. If not stated
otherwise, the following mixtures of purified lipids were used: (i)
a composition mimicking the plasma membrane containing
30.2% (w/w) cholesterol (CH; Sigma-Aldrich), 23.7% (w/w)
phosphatidylethanolamine (PE; from egg yolk), 23.7% (w/w)
phosphatidylcholine (PC, lecithin; from egg yolk) and 22.4% (w/
w) sphingomyelin (SP; from bovine spinal cord; all Grade 1 from
Lipid Products, South Nutfield, Great Britain); (ii) a composition
mimicking the mitochondrial inner membrane (PC/CL) contain-
ing 84% (w/w) PC (Lipid Products) and 16% (w/w) cardiolipin
(CL; Fluka, Buchs, Switzerland). For SPR experiments, 0.1% (w/
w) N-((6-(Biotinoyl)amino)hexanoyl)-1,2-dihexadecanoyl-PE (Bio-
tin-X-DHPE; Molecular Probes, Leiden, Netherlands) was
added. LUVs with a diameter of about 160 nm were prepared
from the lipid stock suspension by a combination of freeze/
thawing and extrusion techniques [52], stored at 4uC and used
within 4 days. The quality of LUVs was routinely checked by
electron microscopy. Preparation of LUVs for leakage assays is
described below.
Vesicle Retention Assay with Chemical Creatine
Determination
Aliquots of LUV suspensions were incubated for 6 min at room
temperature with Cr or PCr at 0, 10, 30, and 100 mM in 10 mM
TES, pH 7.0, 50 mM NaCl. Note that Cr can be used only up to
100 mM due to its solubility limit. After centrifugation for 30 min
at 4uC and 150006g, the pellet was washed twice with 1 ml of
buffer. To hydrolyze PCr to Cr, 0.1 M HCl was added to the
pellet, incubated for 15 min at 90uC, cooled down to room
temperature, and neutralized with 0.1 M NaOH. Cr in hydro-
lyzed and non-hydrolyzed samples was determined by diacetyl-
alpha-napthol reaction according to [53].
Surface Plasmon Resonance Spectroscopy (SPR)
Binding analysis of Cr, PCr, glucose and analogues to model
lipid LUVs was performed by SPR with a T100 Biacore
instrument (GE Healthcare, France). For each programmed series
of measurement cycles, the four lanes of a CM5 sensor chip were
coated with streptavidin (Sigma-Aldrich) and either used to
immobilize 1500 RU biotinylated LUVs (CH/PE/PC/SP or
PC/CL) or left empty (controls) as described [52,54]. Each
measurement cycle (immobilisation of LUVs, contact phase and
dissociation phase of 240 s each, surface regeneration) was
performed with running buffer (10 mM TES, pH 7.0, 50 mM
NaCl) at a flow rate of 10 ml/min and 25uC. Metabolites (Cr, PCr,
glucose or analogues) were injected into the flow over all four lanes
of the sensor chip. After dissociation, the original baseline was
PCr/Phospholipid Interaction
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recovered by injecting 100 mM NaCl for 10 s and an additional
washing step. For each series of measurement cycles, the surface
was regenerated with 0.5% SDS to remove LUVs. Binding was
determined as difference signal between LUV-covered and empty
streptavidin surfaces and quantified by the SPR signal remaining
after 60 s of dissociation. This is preferable to avoid potential
problems due to interference of strong bulk refractive index
changes at high metabolite concentrations during association
phase. Since the SPR signal depends not only on the number but
also on the molecular mass of the bound analyte, SPR data were
expressed as response units (RU) divided by the molecular mass
(Da) of the corresponding analyte.
NMR Measurements
For NMR experiments, a CH/PE/PC/SP lipid suspension
(150 mg/ml in 10 mM TES, pH 6) containing 30.2% (w/w) CH,
23.7% (w/w) dimyristoyl PE (DMPE), 23.7% (w/w) dimyristoyl
PC (DMPC), and 22.4% (w/w) bovine brain SP (all from Avanti
Polar Lipids, Alabaster, AL, USA) were mixed with freshly
prepared solutions of Cr, PCr or glucose (final concentrations:
75 mg/ml for lipids, 25 mM for Cr, PCr, and glucose), or
equivalent volume of TES buffer alone (control). This suspension
containing spontaneously formed vesicles was submitted to five
cycles of freezing, thawing and vortexing, resulting in the
formation of multilamellar vesicles (MLV). The suspension was
centrifuged (10 min, 240006g, 30uC) and the pellets were
transferred into Chemagnetics 4 mm NMR rotors. Experiments
were performed at a magnetic field of 7.0 Tesla with a Varian
Infinity+ spectrometer and a double resonance Chemagnetics
MAS probehead. In the static 31P NMR experiments the length of
the 90u pulses was 6.3 ms, the spectral width 50 kHz, the recycle
delay 3 s. Continuous wave 1H decoupling was employed with
a 1H decoupling strength of 30 kHz. All experiments were
performed with freshly prepared samples.
Differential Scanning Calorimetry (DSC)
DSC runs were performed using 3 mM 1-stearoyl-2-oleoyl PC
(SOPC; Avanti Polar Lipids) suspensions. Lipid films were
hydrated with either buffer alone (20 mM PIPES pH 7.4, 1 mM
EDTA, 140 mM NaCl) or with added 100 mM PCr, Cr or N,N-
dimethylbiguanidinium chloride (DMBG; Sigma, Canada). In
additional experiments, either NaCl was replaced by an equivalent
concentration of guanidine-HCl, or 140 mM NaCl/100 mM PCr
(disodium salt) were replaced by 500 mM PCr (disodium salt) or
by PCr (di(Tris) salt) without additional salt. Thermograms were
obtained by heating-cooling cycles between 0 and 15uC. The shifts
in temperature with respect to SOPC were recorded for two
successive heating-cooling cycles. The experiments were repeated
three times and the transition temperatures averaged.
Leakage Assay
LUVs (100 nm in diameter) consisting of 30.2% CH, 23.7% 1-
palmitoyl-2-oleoyl PE (POPE), 22.4% 1-palmitoyl-2-oleoyl PC
(POPC), and 23.7% bovine brain SP (all from Avanti Polar Lipids)
were generated by extrusion, entrapping at the same time
a mixture of 8-aminonaphthalene-1,3,6-trisulfonate (ANTS) and
the cationic quencher p-xylene-bis-pyridinium bromide (DPX;
both from Invitrogen, Canada). Fifty mM of LUVs were then
placed in buffer alone (20 mM PIPES pH 7.4, 1 mM EDTA,
140 mM NaCl) or in buffer containing 100 mM PCr, Cr or
DMBG, with osmolarity of all solutions adjusted to the same value
as the buffer itself and that of the ANTS/DPX that was entrapped
in the vesicles (about 320 mOsm). Leakage was induced with
500 nM melittin (Sigma, Canada). Fluorescence dequenching of
the ANTS/DPX mixture due to leakage into solution was
monitored at 360 nm excitation/530 nm emission for 200 s,
before full permeabilization of LUVs with 20% Luberol PX to
a final concentration of 0.1% in the cuvette. Each compound was
tested twice.
Red Blood Cell Hemolysis Assay
Blood from a freshly slaughtered pig obtained from the local
slaughterhouse (Abattoir de Grenoble, France) was mixed with an
anticoagulant (citrate buffer) and centrifuged for 15 min at
15006g at room temperature. The pellet consisting of red blood
cells (RBC) was washed four times with phosphate buffered saline
(containing 140 mM NaCl, 1.5 mM KH2PO4, 7.5 mM Na2HPO4
and 10 mM glucose). The final pellet was resuspended in
phosphate buffered saline, stored at 4uC and used for assays
within 2–3 days. For assays, the concentration of RBC was
adjusted to the concentration yielding 1.97–2.00 OD (575 nm)
after full hemolysis induced by distilled water. In the hemolysis
assay, RBC suspension in buffer (30 mM Hepes pH 7.4 for
doxorubicin or hypoosmotic stress assay, phosphate buffered saline
for saponin assay) was preincubated for 10 min under constant
shaking without or with 50 mM PCr, glucose or glucose-6-
phosphate (Glc-6-P); osmolarity was adjusted with NaCl to ca. 330
mOsm. Then, lysing agent was added (1–10 mg/ml saponin,
300 mM doxorubicin; both from Sigma-Aldrich) or for hypoos-
motic stress, the preincubated RBC were placed in hyposmotic
medium (200 mOsm) and incubated (in presence of the tested
metabolites) on a shaker at room temperature (saponin, hypoos-
motic stress) or 37uC (doxorubicin) for time periods of 5 h
(doxorubicin) or 10 min (saponin, hypoosmotic stress). After
centrifugation of samples for 20 s at 150006g, hemoglobin
concentration in the supernatant was measured spectrophotomet-
rically at 575 nm. For each blood sample, results were normalized
to full hemolysis induced by resuspension in distilled water. The
stability of PCr under the given conditions during the entire
experiment was checked by HPLC.
Molecular Model
Representations of molecular structures were prepared in
WebLabViewer Pro v4.0. PDB files for Cr and PCr were from
the human metabolome database (http://www.hmdb.ca), acces-
sion numbers HMDB00064 (Cr) and HMDB01511 (PCr). The
PDB file for the eight dioleoyl PC (DOPC) phospholipids is a subset
of a molecular dynamics simulation of 200 DOPC molecules in the
gel phase, published by Heller and colleagues [55] (GEL.PDB
available http://www.lrz.de/˜heller/membrane/membrane.html).
The solvent-accessible surface area of Cr and PCr was calculated
by WebLab Viewer Pro 4.0 using a probe radius of 1.4 A˚. PCr was
manually docked onto a part of the modeled DOPC surface
consisting of eight phospholipids.
Results
Phosphocreatine and Creatine Both Co-sediment with
Liposomes
Liposomes in form of LUVs consisting of 84% phosphatidyl-
choline (PC) and 16% cardiolipin (CL), which mimic the
mitochondrial inner membrane, have been used in several of
our earlier studies to analyze binding of mitochondrial kinases
to such membranes by surface plasmon resonance (SPR)
[52,56,57]. When we included substrates of CK at physiological
concentrations (10–30 mM), dissociation profiles indicated low
PCr/Phospholipid Interaction
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level binding of PCr (not shown). To confirm such observations,
the same LUVs were incubated with Cr or PCr, washed twice
and subjected to biochemical quantification (Fig. 1). The data
showed concentration-dependent association of Cr and PCr with
the PC-CL liposomes that was much stronger with PCr
compared to Cr.
Phosphocreatine and Analogues Bind Phospholipids in
Surface Plasmon Resonance
In the following, the interaction of Cr and PCr, but also of their
synthetic cyclic analogues cCr and PcCr as well as glucose and
Glc-6-P as controls were analyzed more systematically. We used
an SPR application developed in our earlier studies on protein/
membrane interactions [52,54,56–58] as a direct and quantitative
biophysical method. The PC/CL-LUVs as above were compared
with plasma membrane-like LUVs consisting of cholesterol,
phosphatidylethanolamine, phosphatidylcholine and sphingomye-
lin (CH/PE/PC/SP). SPR measurements of low affinity interac-
tions requiring high concentrations of injected binding partner can
only be performed during dissociation phase; we chose a reporting
point after 60 s of dissociation (Fig. 2). The SPR data provide first
direct evidence for concentration-dependent, saturable PCr
binding to CH/PE/PC/SP-LUVs that was slightly higher than
with Glc-6-P and much higher as compared to Cr or glucose.
From the concentration-dependence of binding, a KD for PCr can
be estimated to be around 100 mM (Fig. 2A). However, all
compounds with a phosphate moiety showed interaction with both
types of membrane in the SPR assay (Fig. 2B,C). PCr also bound
to pure PC-LUVs, albeit much weaker (not shown). Finally, it is to
note that the SPR response of PCr (and Glc-6-P) of up to 40 RU
(after 60 s of dissociation and at 100 mM PCr) is remarkable for
such a low Mr compounds. Extrapolated to end association levels,
this would correspond to more PCr molecules than could be
accommodated in a single layer at the LUV surface. However, the
SPR response is also a function of the distance of bound material
from the biosensor surface. Thus, a change in LUV shape,
compacting the liposome towards the surface, could also explain
the high SPR response.
Creatine and Phosphocreatine Induce Changes in 31P-
NMR Lipid Spectra
Further studies were limited to PCr and Cr as the archetype
guanidino compounds. Interaction of PCr and Cr with CH/PE/
PC/SP membranes was further analyzed by solid-state 31P-NMR,
using multilamellar vesicles (MLVs).
The 31P-NMR lineshape of phospholipid liposomes is de-
termined by the chemical shielding tensor and by the orientation
of the phospholipid molecules with respect to the static magnetic
field B0. In the bilayers in the liquid-crystalline phase the
phospholipid molecules undergo fast (in the NMR time scale)
rotation about the bilayer normal which partially averages the
chemical shielding tensor, resulting in an axially symmetric tensor.
The characteristic 31P NMR spectrum of a spherical liposome is
an axially symmetric powder pattern with a high-field peak and
a low-field shoulder, corresponding to the phospholipids oriented
with the long axis perpendicular and parallel to B0, respectively
(Fig. 3A). A preferential orientation of the phospholipids with the
normal perpendicular to B0 would alter such lineshape, in
particular with a reduced intensity of the low field shoulder [59].
We have detected such effect on the 31P-NMR signal of
phospholipid MLV upon addition of PCr and, to less extent, of
Cr (Fig. 3B). In fact, the spectra in Fig. 3 B show a decrease in the
low intensity edge relative to the high intensity edge at -13.5 ppm
(* in Fig. 3B). The control experiment where glucose was added to
the MLV did not show any effect (Fig. 3C).
It can be concluded that PCr (and possibly much less so Cr)
interact with the lipid bilayers and might induce a preferential
orientation of the phospholipid bilayer with the normal perpen-
dicular to the magnetic field. In addition, the Cr-spectrum reveals
a narrow peak at 0 ppm (** in Fig. 3B) that is missing in other
spectra. The resonance at 0 ppm corresponds to the isotropic
chemical shift of phospholipids and indicates the presence of fast-
tumbling lipid aggregates, possibly due to the occurrence of small
micelles. Finally, the PCr-spectrum shows the typical narrow peaks
due to inorganic phosphate generated by minor PCr hydrolysis
(1.9 ppm) and the PCr itself (23.2 ppm).
Phosphocreatine Changes the Phase Transition
Properties of Lipids
Next we were interested in analyzing the effect of PCr and Cr
binding on lipid membrane properties. We tested the ability PCr,
Cr and DMBG (metformin) to change the phase transition
properties of stearoyloleoyl phosphatidylcholine (SOPC). This
lipid has a gel to liquid crystalline phase transition at ,5uC,
allowing compounds to be tested for their effects on the phase
transition without heating to high temperatures. As shown in
Fig. 4A, PCr raised the temperature of phase transition and thus
stabilized the gel phase of SOPC relative to the liquid crystalline
phase. Cr had no effect (or a small positive DTm) and DMBG had
a negative DTm. To test if the effect was related to salting-out/
salting-in effects, we also used guanidine hydrochloride in place of
NaCl, and obtained an increase in the phase transition temper-
ature with PCr, showing that there was little effect of the anion
(data not shown).
Since the temperature shifts in the experiment shown in Fig. 4A
were small although well reproducible, we repeated these
experiments at a higher concentration of PCr (500 mM) and
compared the PCr-Na salt used throughout this study with the Tris
salt, omitting any other cations as NaCl. As expected, this led to
Figure 1. Phosphocreatine and creatine are retained by
liposomes as determined in a biochemical assay. LUVs consisting
of phosphatidylcholine and cardiolipin (PC/CL) were incubated either
with Cr or PCr at different concentrations in TES buffer (10 mM pH 7.0,
50 mM NaCl), centrifuged, the pellet washed twice, and remaining Cr
and PCr quantified. Data are given as mean6SD (n = 3).
doi:10.1371/journal.pone.0043178.g001
PCr/Phospholipid Interaction
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higher temperature shifts (Fig. 4B), and again no effect of the
cation could be observed. Therefore, the observed shifts in phase
transition temperature were due to interaction of PCr with the
lipid and not to a solvent-type effect.
Membrane-stabilizing Effects
To further study consequences of PCr binding on lipid
membrane properties, we used strong membrane-permeabilizing
treatments to challenge two very different membrane systems,
model lipid vesicles and intact cells. First, CH/POPE/POPC/SP-
LUVs were loaded with a mixture of ANTS and DPX at
concentrations at which the ANTS fluorescence is quenched.
These liposomes were then subjected to a standard leakage assay
using the peptide melittin as a pore forming agent. PCr, and to
smaller extent also Cr and less so DMBG, prevented permeabi-
lization of LUVs by melittin (Fig. 5). Second, we used a classical
hemolysis assay with red blood cells (RBC) to demonstrate that
PCr protects RBC from noxious insults by doxorubicin (Fig. 6A),
hypoosmotic stress (Fig. 6B) and saponin (Fig. 6C). Hemolysis
induced by doxorubicin can serve as a model of membrane
damage related to oxidative stress [60,61]. Supraclinical doxoru-
bicin concentration of 300 mM induced hemolysis over a 5 h
observation period. PCr significantly inhibited hemolysis during
this time period (Fig. 6A). PCr also reduced hemolysis induced by
hypoosmotic stress and the mild detergent saponin (Fig. 6B,C).
Protection from membrane permeabilization was also exerted, to
variable degree, by Glc-6-P, which indicates that for the observed
protective effects, as with the observed membrane interaction, the
phosphate moiety plays an important albeit not exclusive role.
Discussion
The pleiotropic beneficial effects of Cr supplementation are
mainly thought to arise from the increased synthesis of the high
Figure 2. Direct interaction of phosphocreatine, creatine, their cyclic analogues, glucose and glucose phosphate with liposomes as
determined by surface plasmon resonance. (A) Concentration-dependence of glucose (Glc, white), Cr (dark grey), glucose-6-phosphate (Glc-6-P,
light grey), and PCr (black) binding to LUVs consisting of cholesterol, phosphatidylethanolamine, phosphatidylcholine, and sphingomyelin (CH/PE/
PC/SP). (B, C) Binding of PCr, Cr, their cyclic analogues, as well as glucose and Glc-6-P to LUVs consisting of either (B) CH/PE/PC/SP or (C) PC/CL. Runs
were performed in TES buffer (10 mM pH 7.0, 50 mM NaCl). Bound metabolites were quantified at a reporting point 60 s after beginning of
dissociation. The given SPR signal corresponds to measured response units (RU) divided by the molecular mass (Da) of the corresponding metabolite.
Data in (A) were normalized to the response at 100 mM PCr. All data are given as mean 6 SD (n = 4 independent experiments).
doi:10.1371/journal.pone.0043178.g002
Figure 3. Interaction of phosphocreatine and creatine with lipid vesicles as visualized by solid-state 31P-NMR spectroscopy. (A)
Simulation of the static 31P-NMR spectrum of a spherical liposome. (B), (C) Static spectra of lipid vesicles (CH/PE/PC/SP) incubated with (B) 25 mM Cr
or PCr, or (C) 25 mM glucose were compared to spectra of control MLVs without additions. Spectra were recorded at 300 MHz and 303 K, referenced
to 85% H3PO4 and normalized. Differences between control and treated lipid vesicles observed in (B) but not in (C) are indicated: (*) change in the
lineshape in the powder spectrum of Cr and PCr; (**) small resonance peak at ,0 ppm in the Cr spectrum due to isotropic lipids (micelles or other
small aggregates); (#) resonance peak at 1.9 ppm in the PCr spectrum corresponding to inorganic phosphate; (##) resonance peak at 23.2 ppm in
the PCr spectrum corresponding to the phosphate moiety of PCr.
doi:10.1371/journal.pone.0043178.g003
PCr/Phospholipid Interaction
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energy intermediate PCr, thus improving the cellular PCr/ATP
ratio energy status, while anti-cancer effects of synthetic cCr were
proposed to be based on inhibition of CK-mediated PCr synthesis
[1–6]. Cr or cCr uptake and intra-cellular accumulation, and
probably also conversion to the phosphorylated compounds, seem
to be a prerequisite for most effects of Cr or cCr supplementation,
but an exclusive bioenergetic function of the CK/PCr system has
been questioned. Many beneficial effects of Cr and analogues that
are linked to cell signaling and cell protection [9,10,21,22] do not
relate to bioenergetics, and some studies directly challenged an
involvement of bioenergetics [32]. Among the proposed additional
functions are direct anti-oxidative effects of Cr [39] and
membrane stabilization by PCr [49]. However, the anti-oxidative
capacity of Cr in vitro is low, and mechanistic, quantitative
evidence for membrane interaction has been scarce. In the present
study, several independent biochemical and biophysical ap-
proaches including chemical detection, SPR, 31P-NMR, and
DSC were applied to resolve this issue. All methods consistently
Figure 4. Effect of phosphocreatine, creatine and dimethylbiguanidium chloride on the lipid phase transition as determined by
differential scanning calorimetry. Thermograms (left) and quantified phase transition temperature shifts (right) obtained by heating or cooling
of a suspension of SOPC in PIPES buffer (20 mM PIPES pH 7.4, 140 mM NaCl, 1 mM EDTA) alone (middle scans in A or B, labeled (2). (A) one heating
and one cooling scan shown with added 100 mM PCr, Cr or dimethylbiguanidium chloride (DMBG), or (B) two cycles of heating and cooling shown
for each sample. 500 mM PCr Na-salt or Tris-salt (omitting NaCl). Thermograms (left) are from representative runs, histograms (right) represent
averaged data from 3 independent experiments (H = heating; C = cooling).
doi:10.1371/journal.pone.0043178.g004
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demonstrated that PCr can indeed (i) directly bind to phospho-
lipid-containing membranes albeit with low affinity, (ii) alter
structural and conformational parameters of phospholipid lipo-
somes, and (iii) protect phospholipid liposomes and erythrocytes
from permeabilization induced by melittin, doxorubicin, hypoos-
motic stress or saponin.
Binding of Cr, PCr and analogues to model membranes
mimicking the lipid composition of the plasma membrane and the
inner mitochondrial membrane was quantified biochemically and
more extensively by surface plasmon resonance spectroscopy.
High binding levels were observed for the phosphorylated species
(PCr, PcCr, and also Glc-6-P). More significant effects of the
phosphorylated form of Cr have been also observed in earlier
studies on preservation of organ transplants when added to
cardioplegic solutions [47,49] and on protection from oxidative
damage [62]. Since the PCr infused with cardioplegic solutions is
unlikely to transverse biomembranes, due to its charge, it has to be
assumed that it will bind to the outer leaflet of cellular plasma
membranes in a similar fashion as intracellular PCr formed by CK
from Cr would interact with the inner leaflet of the same
membrane. Our data further show that the linear and cyclic
guanidino compounds examined here behave similarly in respect
to their membrane binding capacity. This is quite in contrast to
their function as CK substrates, where Cr/PCr allow reversible
catalysis, while cCr is rather trapped into PcCr [30]. However, this
observation would be consistent with similar anticancer effects
observed for Cr and cCr [29,31].
Figure 5. Phosphocreatine and creatine protect lipid vesicles
against melittin-induced permeabilization. 50 mM of CH/POPE/
POPC/SP-LUVs entrapping a quenched ANTS/DPX solution were
injected into PIPES buffer (20 mM pH 7.4, isomolarity of the entrapped
solution was adjusted to be equal to that of the external media with
NaCl). The media external to the liposomes contained only phosphate
buffer and NaCl (trace 1) or 100 mM DMBG (trace 2), Cr (trace 3), or PCr
(trace 4). Leakage was begun with 500 nM melittin. All buffers and
entrapped ANTS/DPX solution were adjusted to the same osmolarity
and each compound was tested twice. Fluorescence dequenching was
followed at 530 nm and normalized to the signal obtained after full
permeabilization of LUVs.
doi:10.1371/journal.pone.0043178.g005
Figure 6. Phosphocreatine protects red blood cells against doxorubicin-, saponin- and hypoosmotic stress- induced lysis. Red blood
cells isolated from fresh pig blood were preincubated for 10 min without any additions or in presence of 50 mM PCr, glucose (Glc) or glucose-6-
phosphate (Glc-6-P). Hemolysis was induced by (A) 300 mM doxorubicin (DXR) at 37uC, (B) incubation for 10 min at 200 mOsm at room temperature,
or (C) incubation with 1–10 mg/ml saponin for 10 min at room temperature. Data in (A) were corrected for absorbance of doxorubicin; hemolysis was
evaluated directly (0 h) and 5 h after addition of doxorubicin. Stability of PCr under the given experimental condition was verified by HPLC. Data are
given as mean6SD (n = 3). Note: Glc-6-P also exerts a protective effect.
doi:10.1371/journal.pone.0043178.g006
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Membrane interaction of PCr has important physiological
significance, even if it is shared to a certain degree by other
phospho-compounds like Glc-6-P. As a product of the CK
reaction, PCr accumulates within the cell to high concentrations,
reaching several tens of mM in tissues like muscle [1], and as such
it is one of the most abundant metabolites. These concentrations
would be relevant for phospholipid interaction, since our SPR
results suggest a KD of in the higher mM-range. Concentrations of
other phospho-compounds are much lower, with Glc-6-P normally
not exceeding 1 mM [63,64]. Interestingly, however, even for Glc-
6-P some membrane-shielding effects have been suggested e.g. in
the protection against alpha-chaconine-induced developmental
toxicity in Xenopus embryos [65].
The PCr/phospholipid interaction depends on polar interac-
tions, since the phospho-moiety seems to be important for
membrane binding and increasing ionic strength diminished the
interaction in SPR experiments (not shown). In fact, many
phospholipids are zwitterions, with their head group exposing at
least one negative phosphate and one positive nitrogen-containing
group. Also all examined guanidino compounds have a zwitterionic
character due to their guanidino and carboxyl groups, and an
additional full negative charge is present in the phosphorylated
compounds (Fig. 7A,B). Interestingly, another zwitterion, taurine,
has repeatedly been reported to interact with phospholiposomes
[66] or cell membranes [67]. With their alternating positive and
negative surface potential (Fig. 7A), these compounds are well
suited to intercalate between and crosslink the zwitterionic
phospholipid head groups, with the larger phosphorylated
compounds carrying three different charged surfaces being more
efficient. Indeed, the molecular dimensions of PCr fit very well to
the distances of head groups in a planar PC membrane of 6–10 A˚,
allowing for numerous polar interactions (Fig. 7C). This would
explain the enhanced phospholipid packing suggested by increased
lipid phase transition temperature. However, additional binding
determinants may contribute to the observed membrane stabiliz-
ing effect, such as sterical accessibility, distance of polar groups in
the lipids [68], cooperative phenomena, or the initial fluidity of the
membrane.
Changes in the properties of lipid bilayers induced by PCr
binding were very clearly indicated by our 31P-NMR and DSC in
vitro experiments, as well as in cell-based RBC protection assays.
31P-NMR detected a distortion in the lineshape of the 31P-NMR
signal upon addition of PCr (and much less so Cr). Several
examples of such alteration of the powder spectrum have been
reported in literature and have been attributed to a preferential,
magnetically-induced orientation of the bilayer with the normal
perpendicular to the magnetic field which results in the de-
formation of the spherical liposomes to prolate ellipsoids [59,69–
71]. The macroscopical magnetic orientation observed in
phospholipids in magnetic fields is due to the anisotropy of their
magnetic susceptibility [70]. Generally, the corresponding energy
contribution is smaller than the thermal energy and the membrane
curvature energy and does not affect the axially symmetric 31P
NMR powder pattern. On the other side, systems where the
magnetic energy is large will show a preferential orientation of
lipid bilayers. Factors which affect the extent of the magnetically
induced orientation are, for instance, the strength of the static
magnetic field, the size of the liposomes, the bulk viscosity, the
bending elastic energy of the membrane, and the anisotropy of the
magnetic susceptibility of the phospholipids upon binding of
lipophilic molecules [70]. The addition of PCr (and possibly Cr)
could induce a preferential orientation of the lipid vesicles for
instance, by affecting the elasticity of the membrane, the size of the
liposomes, or the total anisotropy of the magnetic susceptibility of
the metabolite-lipid system. The influence of PCr on liposome
shape as indicated by NMR could also explain the relatively strong
SPR signal, because such a change could add to the signal due to
metabolite binding to the liposome surface.
Direct evidence for altered membrane properties induced by
PCr binding was provided by DSC. PCr binding led to a small but
specific and significant shift in the phase transition temperature of
a model lipid, corroborating the hypothesis of enhanced mem-
brane packing. This interpretation is also consistent with earlier
data on increased structural order in PCr-treated cardiac
sarcolemmal preparations [49] or motional restriction of Cr and
PCr in muscle [51]. Physiologically relevant effects of PCr/
phospholipid interaction were evidenced by experiments with
LUVs and red blood cells (RBC). PCr efficiently protected
membranes and cells against lysis induced by a membrane
permeabilizing peptide, a mild detergent, oxidative or hypoosmo-
tic damage. Thus, the more tight packing of membrane lipids or
even the presence of PCr itself protects sensitive lipid residues from
different kinds of damaging agents, in particular from oxidation.
The fact that under most conditions the protective effect of PCr is
moderate does not diminish its potential in vivo significance.
Identification of mainly PCr (and PcCr) as interactors with
phospholipids gives new mechanistic insight into the biological
action of these guanidino compounds. First, it suggests that the
presence of active CK is essential to generate the more potent PCr
from Cr in vivo. This is also true for nutritional supplementation or
intravenous injection, since PCr is prone to hydrolysis at acidic pH
and does not represent a substrate for cellular uptake by the Cr
transporter [17]. Second, and most importantly, phospholipid
binding of PCr, Cr or their cyclic analogues could account for
protective effects that are not exclusively related to high-energy
phosphoryl transfer and the cellular energy state. An important
example is the protection by Cr from oxidative stress, which
induces harmful modifications of various biomolecules, including
membrane phospholipids, in many pathological states like
ischemia/reperfusion injury in heart or brain, or in acute and
chronic heart failure [72,73], neurodegenerative and neuromus-
cular diseases [74,75], as well as in aging [76]. Protective effects of
Cr have been reported for all these pathologies (for review see [1–
5]), and depletion of intracellular PCr often correlated with
membrane destabilization and destruction [47,77]. In particular in
ischemic myocardium PCr has been shown to inhibit process of
sarcolemmal phospholipid degradation to lysophosphoglycerides
[78]. Thus, favouring higher PCr levels would be beneficial for
both, cell energetics and membrane structure. Since extracellular
PCr is unlikely to transverse plasma membranes but obviously can
bind to and interact with the outer leaflet of plasma membranes,
our data explain the enigmatic fact that externally applied PCr in
cardioplegic solutions displayed significant cardiac protection [79–
81]. Other examples are the anti-tumor and neuroprotective
activities found in different experimental systems for all guanidino
compounds tested here, cCr or PcCr, as well as Cr or PCr
[26,29,31,33], although cCr and PcCr are unlikely to improve
cellular energetics. As with PCr, the accumulating PcCr seems to
be the active compound, since e.g. CK activity is mostly necessary
for the inhibitory effect of cCr on tumor growth [26,27].
The direct interaction of these guanidino compounds with
membrane phospholipids and the resulting modulation of mem-
brane properties, including phospholipid packing and membrane
stabilization, could not only have protective effects in pathological
situations, but may also play a role under normal physiological
conditions where membrane-bound PCr may be important for
membrane topology or membrane-related processes. Lipid in-
teraction of PCr, leading to specific pools of membrane bound
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Figure 7. Structure and putative phospholipids interaction mechanism of phosphocreatine and its analogues. (A) Chemical structures
of Cr, PCr (top) as well as the electrostatic potential (red, positive; blue, negative) at the solvent-accessible surface (mesh representation),
superimposed on the ball-and-stick representations of Cr and PCr (bottom). (B) Chemical structures of the cyclic analogues cCr and PcCr. (C) Proposed
interaction between PCr (bold line representation) and the zwitterionic headgroups of an array of eight dioleoyl phosphatidylcholine molecules
(DOPC, thin line representation) with (partial) charges indicated. Structures prepared with WebLabViewer Pro v4.0 (for details see Materials and
Methods).
doi:10.1371/journal.pone.0043178.g007
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metabolites (see [82]), could also play a role in the organization
and efficiency of processes in cellular energy transduction and
metabolite channelling, which are largely membrane bound.
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